references
DEVELOPMENT
State University; Piaui Federal University, Teresina; Sergipe Federal University, Aracaju; Leishmaniasis Control Programme/Ministry of Health; Universidade Estadual do Rio de Janeiro; Hospital Sao José de Doencas Infecciosas, Fortaleza
Ravidasvir/ Sofosbuvir
HEPATITIS C
LPV/r pellets with dual NRTI
PAEDIATRIC HIV
Objective: Conduct a Phase II/III clinical study assessing the efficacy of sofosbuvir + ravidasvir combination as an alternative regimen for the treatment of hepatitis C. Main partners: Pharco Pharmaceuticals, Inc., Egypt; Presidio
Objective: Evaluate the effectiveness of LPV/r pellets in addition to AZT/3TC (or ABC/3TC) paediatric fixed-dose combination (FDCs) tablet in an implementation study in HIV-infected infants and young children who cannot swallow tablets. Main partners: Joint Clinical Research Centre, Uganda; Baylor
Pharmaceuticals, Inc., USA; Clinical Research Malaysia, Ministry of Health, Malaysia
MYCETOMA
Fosravuconazole
College of Medicine Children’s Foundation, Uganda; Epicentre, Uganda; University of Nairobi, Kenya; Gertrude’s Children’s Hospital, Kenya; Kenya Medical Research Institute, Kenya; Associated Medical Sciences/PHPT International Research Unit, Thailand; Department of Health, South Africa; Cipla Ltd., India; UNITAID; St Lumumba Health Centre, Kisumu, Kenya; Mbagathi District Hospital, Kenya; Moi Teaching and Referral Hospital, Kenya; Ministry of Health, Kenya; Clinton Health Access Initiative, USA
Objective: Conduct a randomized controlled clinical study to investigate the efficacy of fosravuconazole for patients with eumycetoma compared to the current treatment, itraconazole. Main partners: Eisai Co. Ltd, Japan; Erasmus Medical Center,
The Netherlands; Radboud University Medical Center, Nijmegen, The Netherlands; Mycetoma Research Centre, Soba University Hospital, Khartoum, Sudan; Institute of Endemic Diseases, Khartoum University, Sudan
• R&D Portfolio
13
